42
Participants
Start Date
June 2, 2023
Primary Completion Date
September 30, 2027
Study Completion Date
June 30, 2028
CA-4948
Provided by Curis, Inc.
Nivolumab
240 mg IV on Day 1 of each cycle
Pembrolizumab
400 mg IV on Day 1 of every 3 cycles (C1D1, C4D1, C7D1,…) and dosing may continue for a max of 2 years
Trastuzumab
6 mg/kg IV loading dose on Cycle 1 Day 1 and 4 mg/kg IV on Day 1 of every subsequent cycle
mFOLFOX7
Standard of care
RECRUITING
Washington University School of Medicine, St Louis
Curis, Inc.
INDUSTRY
The Foundation for Barnes-Jewish Hospital
OTHER
Washington University School of Medicine
OTHER